170 related articles for article (PubMed ID: 28836710)
41. Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.
Basso S; Zecca M; Calafiore L; Rubert L; Fiocchi R; Paulli M; Quartuccio G; Guido I; Sebastiani R; Croci GA; Beschi C; Nardiello I; Ginevri F; Cugno C; Comoli P
Pediatr Transplant; 2013 Nov; 17(7):E168-73. PubMed ID: 23992468
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
Rouphael B; Lankireddy S; Lazaryan A; Kukla A; Ibrahim HN; Matas AJ; Issa N
Clin Transplant; 2016 Jan; 30(1):60-5. PubMed ID: 26497471
[TBL] [Abstract][Full Text] [Related]
43. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
44. [Lymphoproliferative disorders after renal transplantation in a child].
Márquez U S; Peredo G MS; Vogel S A; Ibáñez A P
Rev Med Chil; 2009 Mar; 137(3):405-10. PubMed ID: 19621184
[TBL] [Abstract][Full Text] [Related]
45. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
[TBL] [Abstract][Full Text] [Related]
46. Epstein-Barr virus encephalitis in a renal transplant recipient manifesting as hemorrhagic, ring-enhancing mass lesions.
Babik JM; Katrak S; Miller S; Shah M; Chin-Hong P
Transpl Infect Dis; 2015 Oct; 17(5):744-50. PubMed ID: 26252540
[TBL] [Abstract][Full Text] [Related]
47. An unusual presentation of post-transplant lymphoproliferative disorder mimicking vasculitis in heart transplantation.
Murray DL; Pereira NL; Miller DV
J Heart Lung Transplant; 2008 Nov; 27(11):1257-61. PubMed ID: 18971100
[TBL] [Abstract][Full Text] [Related]
48. Epstein-Barr virus associated with a post-transplant lymphoproliferative disorder presenting as isolated gastrointestinal tract bleeding.
Badham K; Mirchandani A; Arumainayagam N; West DR
Endoscopy; 2007 Feb; 39 Suppl 1():E64-5. PubMed ID: 17323282
[No Abstract] [Full Text] [Related]
49. Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients.
Loar RW; Driscoll DJ; Kushwaha SS; Cramer CH; O'Leary PW; Daly RC; Mauriello DA; Johnson JN
Pediatr Transplant; 2013 Dec; 17(8):794-9. PubMed ID: 24164828
[TBL] [Abstract][Full Text] [Related]
50. The effect of sirolimus-based immunosuppression vs. conventional prophylaxis therapy on cytomegalovirus infection after liver transplantation.
Sheng L; Jun S; Jianfeng L; Lianghui G
Clin Transplant; 2015 Jun; 29(6):555-9. PubMed ID: 25851741
[TBL] [Abstract][Full Text] [Related]
51. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
Santos AH; Casey MJ; Xuerong W; Womer KL
Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742
[TBL] [Abstract][Full Text] [Related]
52. Significance of detecting Epstein-Barr-specific sequences in the peripheral blood of asymptomatic pediatric liver transplant recipients.
Krieger NR; Martinez OM; Krams SM; Cox K; So S; Esquivel CO
Liver Transpl; 2000 Jan; 6(1):62-6. PubMed ID: 10648579
[TBL] [Abstract][Full Text] [Related]
53. De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results.
Meiser B; Buchholz S; Kaczmarek I
Curr Opin Organ Transplant; 2011 Oct; 16(5):522-8. PubMed ID: 21836511
[TBL] [Abstract][Full Text] [Related]
54. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD.
Davis JE; Sherritt MA; Bharadwaj M; Morrison LE; Elliott SL; Kear LM; Maddicks-Law J; Kotsimbos T; Gill D; Malouf M; Falk MC; Khanna R; Moss DJ
Int Immunol; 2004 Jul; 16(7):983-9. PubMed ID: 15159377
[TBL] [Abstract][Full Text] [Related]
55. EBV-induced polymorphic lymphoproliferative disorder of the iris after heart transplantation.
Rohrbach JM; Kröber SM; Teufel T; Kortmann RD; Zierhut M
Graefes Arch Clin Exp Ophthalmol; 2004 Jan; 242(1):44-50. PubMed ID: 14663590
[TBL] [Abstract][Full Text] [Related]
56. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
Wistinghausen B; Gross TG; Bollard C
Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715
[TBL] [Abstract][Full Text] [Related]
57. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression.
Groetzner J; Kur F; Spelsberg F; Behr J; Frey L; Bittmann I; Vogeser M; Ueberfuhr P; Meiser B; Hatz R; Reichart B;
J Heart Lung Transplant; 2004 May; 23(5):632-8. PubMed ID: 15135383
[TBL] [Abstract][Full Text] [Related]
58. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
[TBL] [Abstract][Full Text] [Related]
59. Lymphoproliferative Disease After Pediatric Liver Transplant.
Özçay F
Exp Clin Transplant; 2017 Mar; 15(Suppl 2):79-81. PubMed ID: 28302005
[TBL] [Abstract][Full Text] [Related]
60. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant.
Hymes LC; Warshaw BL
Pediatr Transplant; 2005 Aug; 9(4):520-2. PubMed ID: 16048606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
